Organogenesis Holdings Inc (OQ:ORGO)

Nov 13, 2020 12:45 am ET
Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Nov 10, 2020 05:40 pm ET
Organogenesis Holdings Inc. Announces Proposed Public Offering of Class A Common Stock
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Nov 09, 2020 04:05 pm ET
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Nov 02, 2020 04:30 pm ET
Latest Wound Care Research from Organogenesis Highlighted at SAWC Fall 2020 Virtual Meeting
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Oct 14, 2020 04:30 pm ET
Organogenesis Holdings Inc. Reports Preliminary Financial Results for Third Quarter 2020
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Sep 17, 2020 04:05 pm ET
Organogenesis Holdings Inc. Updates Date and Time of Presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Sep 03, 2020 04:05 pm ET
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Aug 24, 2020 04:05 pm ET
Organogenesis Holdings Inc. Announces Management Change
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Aug 10, 2020 04:05 pm ET
Organogenesis Holdings Inc. Reports Second Quarter and First Half 2020 Financial Results
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Jul 23, 2020 04:05 pm ET
Latest Advanced Wound Care Innovations and Research from Organogenesis to be Highlighted at SAWC Spring | WHS 2020 Virtual Meeting
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Jul 15, 2020 07:30 am ET
Organogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Jun 29, 2020 07:30 am ET
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2020 Financial Results on August 10, 2020
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
May 11, 2020 04:05 pm ET
Organogenesis Holdings Inc. Reports First Quarter 2020 Financial Results
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Apr 13, 2020 04:05 pm ET
Organogenesis Announces Virtual Education Events for April
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Apr 08, 2020 04:05 pm ET
Organogenesis Holdings Inc. Reports Preliminary Revenue Results for First Quarter 2020
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Mar 25, 2020 09:15 am ET
Organogenesis To Sponsor March 26 Webinar, “Taking Control of the Wound Healing Environment,” Featuring Dr. Alisha Oropallo
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Mar 09, 2020 04:05 pm ET
Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2019 Financial Results; Introduces Fiscal Year 2020 Revenue Guidance
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Feb 21, 2020 07:30 am ET
Organogenesis Holdings Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Jan 23, 2020 04:05 pm ET
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2019 Financial Results on March 9, 2020
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Jan 13, 2020 07:00 am ET
Organogenesis Holdings Inc. Reports Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2019
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Nov 21, 2019 10:04 pm ET
Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Nov 19, 2019 04:01 pm ET
Organogenesis Holdings Inc. Announces Proposed Public Offering of Class A Common Stock
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Nov 12, 2019 04:05 pm ET
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Oct 11, 2019 04:05 pm ET
Latest Advanced Wound Care Research from Organogenesis Highlighted at SAWC Fall 2019
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Oct 05, 2019 09:00 am ET
New ReNu® Data from Organogenesis Highlighted at ICRS 2019 World Congress
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Sep 17, 2019 07:30 am ET
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2019 Financial Results on November 12, 2019
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Sep 06, 2019 09:00 am ET
MEDIA ALERT: Organogenesis Holdings Inc. (Nasdaq: ORGO) to Ring the Nasdaq Stock Market Closing Bell
What:Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Gary S. Gillheeney, Sr., President & CEO, will ring the Closing Bell....
Sep 06, 2019 08:00 am ET
Organogenesis Announces Annual College Scholarship Award Winner
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Aug 19, 2019 04:57 pm ET
Organogenesis Announces Completion of Exchange Offer and Plan to Exchange Remaining Outstanding Public Warrants
Organogenesis Holdings Inc. (Nasdaq: ORGO) (the “Company”) announced today the completion of its previously announced exchange offer (the “Offer”) and consent solicitation relating to its publicly traded warrants. On August 19, 2019, the Company...
Aug 09, 2019 07:00 am ET
Organogenesis Holdings Inc. Reports Second Quarter and First Half 2019 Financial Results
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
Jul 22, 2019 04:15 pm ET
Organogenesis Holdings Commences Offer to Exchange Class A Common Stock for any and all Outstanding Public Warrants and Consent Solicitation
Organogenesis Holdings Inc. (Nasdaq: ORGO) (the “Company,” “we” or “our”) today announced that it has commenced an offer to exchange (“Offer to Exchange”) 0.095 shares of the Company’s Class A common stock (“Class A Common Stock”) for each...
Jul 08, 2019 08:00 am ET
Organogenesis Announces 2019 Sponsorship of American Podiatric Medical Association Educational Programs and Annual Scientific Meeting
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Jul 01, 2019 07:30 am ET
Organogenesis Joins Russell 2000®, Russell 3000® and Russell Microcap® Indexes
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced...
Jun 06, 2019 04:05 pm ET
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2019 Financial Results on August 9, 2019
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
May 10, 2019 07:08 am ET
Organogenesis Holdings Inc. Reports First Quarter 2019 Financial Results
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today...
May 01, 2019 08:30 am ET
Organogenesis Receives Innovative Technology Contract from Vizient
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced...
Apr 30, 2019 08:30 am ET
Latest Wound Care Research from Organogenesis Highlighted at SAWC Spring 2019
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced...
Apr 02, 2019 07:30 am ET
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2019 Financial Results on May 10, 2019
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Apr 01, 2019 08:30 am ET
Organogenesis Compliant With Nasdaq Listing Criteria
Organogenesis Holdings Inc. (the “Company”) (Nasdaq:  ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine...
Mar 18, 2019 04:05 pm ET
Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Mar 14, 2019 04:05 pm ET
Organogenesis Holdings Inc. Announces New $100 Million Credit Agreement with Silicon Valley Bank and MidCap Financial
CANTON, Mass., March 14, 2019 /PRNewswire/ -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced a new credit agreement with Silicon Valley Bank, the lead agent, and MidCap Financial. The agreement provides for a credit facility in the aggregate principal amount of $100 million, consisting of a $60 million term loan facility and a $40 million revolving credit facility.  The agreement contains...
Mar 12, 2019 09:00 am ET
Organogenesis Holdings Inc. Announces ReNu® Clinical Trial Results at AAOS 2019 Annual Meeting
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Mar 11, 2019 07:30 am ET
Organogenesis Holdings Inc. to Present at Oppenheimer’s 29th Annual Healthcare Conference
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Mar 04, 2019 09:00 am ET
New Study Shows PuraPly® Antimicrobial Positively Impacts Course of Healing Across Variety of Wound Types
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Feb 25, 2019 08:00 am ET
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2018 Financial Results on March 18, 2019
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today...
Jan 24, 2019 10:00 am ET
Organogenesis to Sponsor Jan. 30 Webinar, “Chronic Wounds and Biofilms: Advancing Assessment and Treatment,” Featuring Dr. Gregory Schultz
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, will...
Jan 07, 2019 04:54 pm ET
Organogenesis Holdings Inc. Receives Positive Nasdaq Listing Determination
CANTON, Mass., Jan. 7, 2019 /PRNewswire/ -- Organogenesis Holdings Inc. (the "Company") (Nasdaq: ORGO; ORGOW) today announced that on January 4, 2019, the Company was notified by The Nasdaq Stock Market LLC ("Nasdaq") that, based on the plan of compliance presented by the Company at its hearing, the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for the continued listing of its Class A common stock on The Nasdaq Capital Market. Pursuant to the Panel's decision, on or before March 31, 2019, the Company is required to demonstrate to the satisfaction of Staff and the Pane...
Jan 07, 2019 04:15 pm ET
Nasdaq Scheduled Resumption in Organogenesis Holdings Inc.
The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading in Organogenesis Holdings Inc. (Nasdaq: ORGO) is scheduled to resume on Tuesday, January 8, 2019, at 7:15 a.m. Eastern Time.  Trading in the company’s stock was halted on October 30,...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.